Spots Global Cancer Trial Database for lkb1
Every month we try and update this database with for lkb1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | NCT05887492 | Non Small Cell ... Solid Tumors, A... Endometrial Can... Pancreatic Canc... Cervical Cancer Breast Cancer Carcinoma of Un... | TNG260 Pembrolizumab | 18 Years - | Tango Therapeutics, Inc. | |
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | NCT05887492 | Non Small Cell ... Solid Tumors, A... Endometrial Can... Pancreatic Canc... Cervical Cancer Breast Cancer Carcinoma of Un... | TNG260 Pembrolizumab | 18 Years - | Tango Therapeutics, Inc. | |
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | NCT06188208 | Advanced Solid ... Advanced Hemato... | VVD-130850 Pembrolizumab | 18 Years - | Vividion Therapeutics, Inc. |